ES2807550T3 - Composiciones y procedimientos para reducir la inmunogenicidad específica del antígeno - Google Patents

Composiciones y procedimientos para reducir la inmunogenicidad específica del antígeno Download PDF

Info

Publication number
ES2807550T3
ES2807550T3 ES14848904T ES14848904T ES2807550T3 ES 2807550 T3 ES2807550 T3 ES 2807550T3 ES 14848904 T ES14848904 T ES 14848904T ES 14848904 T ES14848904 T ES 14848904T ES 2807550 T3 ES2807550 T3 ES 2807550T3
Authority
ES
Spain
Prior art keywords
opls
fviii
antigen
composition
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14848904T
Other languages
English (en)
Spanish (es)
Inventor
Sathy Balu-Iyer
Matthew P Kosloski
Krithika Arun Shetty
Jennifer Schneider
Anas Fathallah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation of the State University of New York
Original Assignee
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Foundation of the State University of New York filed Critical Research Foundation of the State University of New York
Application granted granted Critical
Publication of ES2807550T3 publication Critical patent/ES2807550T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C07F9/106—Adducts, complexes, salts of phosphatides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES14848904T 2013-09-24 2014-09-24 Composiciones y procedimientos para reducir la inmunogenicidad específica del antígeno Active ES2807550T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361881857P 2013-09-24 2013-09-24
PCT/US2014/057234 WO2015048145A1 (en) 2013-09-24 2014-09-24 Compositions and methods for reducing antigen-specific immunogenicity

Publications (1)

Publication Number Publication Date
ES2807550T3 true ES2807550T3 (es) 2021-02-23

Family

ID=52744422

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14848904T Active ES2807550T3 (es) 2013-09-24 2014-09-24 Composiciones y procedimientos para reducir la inmunogenicidad específica del antígeno

Country Status (6)

Country Link
US (1) US20160243220A1 (enExample)
EP (1) EP3049103B1 (enExample)
JP (1) JP6783652B2 (enExample)
CN (1) CN105992591A (enExample)
ES (1) ES2807550T3 (enExample)
WO (1) WO2015048145A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12697320B2 (en) 2021-01-29 2026-08-04 Tim Therapeutics, Inc. Tartaric acid analogs and uses thereof
US20240173389A1 (en) * 2021-03-11 2024-05-30 Lapix Therapeutics, Inc. Compositions and Methods For Reducing Immune Intolerance
EP4384495A1 (en) * 2021-08-13 2024-06-19 Lapix Therapeutics, Inc. Compositions and methods for reducing immune intolerance and treating autoimmune disorders
CN117940407A (zh) 2021-08-13 2024-04-26 Lapix生物治疗股份有限公司 降低免疫不耐受和治疗自身免疫病症的组合物和方法
US20260144239A1 (en) 2022-10-25 2026-05-28 Lapix Therapeutics, Inc. Immune Cell-Engrafted Non-Human Animals and Non-Human Animal Models
WO2024118602A1 (en) 2022-11-29 2024-06-06 Lapix Therapeutics, Inc. Compositions and methods for reducing immune intolerance and treating autoimmune disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625584B2 (en) 2000-11-30 2009-12-01 The Research Foundation Of State University Of New York Method of complexing a protein by the use of a dispersed system and proteins thereof
US8110218B2 (en) 2000-11-30 2012-02-07 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein-lipid complexes
US7351688B2 (en) * 2003-02-05 2008-04-01 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein formulations
US7875288B2 (en) 2006-03-30 2011-01-25 The Research Foundation Of State University Of New York Method for treating blood coagulation disorders
EP2007357B1 (en) * 2006-03-30 2016-11-09 The Research Foundation Of State University Of New York Compositions of less immunogenic and long-circulating protein-lipid complexes
WO2011005850A1 (en) * 2009-07-07 2011-01-13 The Research Foundation Of State University Of New York Lipidic compositions for induction of immune tolerance

Also Published As

Publication number Publication date
JP6783652B2 (ja) 2020-11-11
US20160243220A1 (en) 2016-08-25
JP2016531853A (ja) 2016-10-13
WO2015048145A9 (en) 2015-06-25
EP3049103A1 (en) 2016-08-03
EP3049103A4 (en) 2017-09-27
EP3049103B1 (en) 2020-06-24
CN105992591A (zh) 2016-10-05
WO2015048145A1 (en) 2015-04-02

Similar Documents

Publication Publication Date Title
US20250387461A1 (en) Compositions and methods for antigen-specific tolerance
EP3049103B1 (en) Compositions and methods for reducing antigen-specific immunogenicity
US20250319075A1 (en) Phosphoserine containing compositions for immune tolerance induction
Cruz-Leal et al. The vacuolar pathway in macrophages plays a major role in antigen cross-presentation induced by the pore-forming protein sticholysin II encapsulated into liposomes
EP3058953A1 (en) Lipidic compositions for induction of immune tolerance
Yang et al. Reprogramming dysfunctional dendritic cells by a versatile metabolism nano-intervenor for enhancing cancer combinatorial immunotherapy
KR20020012221A (ko) 체액성 및 세포성 면역 반응을 증진시키기 위한, 안정성과생체 적합성이 최적화된 애쥬반트
US20160060324A1 (en) Methods and Compositions for Treating Bleeding Disorders
JP2024069198A (ja) 活性剤及び免疫調節剤のリンパ節への標的化送達のための方法及び組成物
Glassman et al. Phosphatidylserine is not just a cleanup crew but also a well-meaning teacher
Ramani et al. Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A
US10064922B2 (en) Compositions and methods for immune tolerance induction
US11701328B2 (en) Phosphoserine containing compositions for immune tolerance induction
US20220016241A1 (en) Compositions and methods for reducing antigen-specific immunogenicity
Takahashi et al. Phagocytosis of liposome particles by rat splenic immature monocytes makes them transiently and highly immunosuppressive in ex vivo culture conditions
US20230381309A1 (en) Methods of treating diffuse large b-cell lymphoma
US20240245762A1 (en) Methods and platforms for promoting antigen-specific tolerance in the treatment of type 1 diabetes and graft rejection and compositions relating thereto
WO2025257777A1 (en) Materials and methods for improved three-dimensional immunity